Medicament combination for regrouping leech essence

A technology for recombining hirudin and medicines, which is applied in the directions of medicine combinations, medicine formulations, and medical preparations containing active ingredients, and can solve the problems of aggravating HATII and the like

Inactive Publication Date: 2008-04-02
SHANGHAI NEWSUMMIT BIOPHARMA
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In vitro tests have shown that low molecular weight heparin and unfractionated heparin have 78%-88% cross-reactivi...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0009] The purpose of describing the embodiments of the present invention is to better explain how to implement the present invention. The purpose is only to illustrate, but not to limit the invention in any way.

[0010] 82 patients were divided into 4 groups for prospective multi-center phase III clinical trial. The diagnostic criteria of patients are based on clinical. (eg, in a platelet count drop greater than 30% or less than 10 9 / L, and thromboembolic complications concurrently or solely during heparin administration). Antibodies to HAT are also being studied in trials. Patients need to be 18 years old or older and have a definite need for injection antithrombotic therapy or prevention. The following patients were excluded: if the patient required hemodialysis or filtration due to severe renal failure, had poor compliance, was allergic to recombinant hirudin or was pregnant. Each patient provided informed consent to participate in the trial.

[0011] In the test g...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a medicine composition for curing heparin-induced thrombocytopenia. The main components include Lepirudin and salt which can be accepted by the medicine. The medicine composition has value of curing the heparin-induced thrombocytopenia. The Lepirudin in the invention mainly has the following two advantages: (1) light molecular weight and nearly no antigenicity; (2)nearly no toxicity.

Description

technical field [0001] The invention relates to a pharmaceutical combination of recombinant hirudin, which has the effect of treating heparin-related thrombocytopenia. Background technique [0002] Recombinant hirudin is a specific thrombin inhibitor. It is an aglycosylated single-chain polypeptide containing 65 or 66 amino acid residues, with a molecular weight of about 7kD. For disulfide bonds, it stabilizes its spatial conformation; its C-terminus contains more acidic amino acids. [0003] Heparin-associated thrombocytopenia (HAT) is the most serious adverse reaction during heparin therapy. There are 2 types of HAT with very different etiologies. HAT I is that heparin directly activates platelets through non-immune ways, causing platelet aggregation and reduction. In 10% of patients receiving heparin treatment, the platelet count decreased to 100×109 / L on the first 1 to 2 days after administration. But it usually resolves on its own without treatment. HAT II is caused...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K38/17A61P7/00A61P7/04
Inventor 黄阳滨任军严桦
Owner SHANGHAI NEWSUMMIT BIOPHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap